u/ahmed_iyer

Four pharmacies, four prices, same product, same month. The spread was larger than I expected and none of them were the headline offer.

the Irish scheme cap is the single most useful fact in this board

hold the dose that works, the ladder is not a leaderboard

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.

Same. My ICB threshold was different from the neighbouring one and nobody could tell me why.

Same experience with the appetite effect being flatter across the week rather than front-loaded.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

This matches mine. Milder food noise than I expected, and what there was settled inside a fortnight of each step.

tier 3 waiting lists are measured in years, not months

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

research-use-only means not approved for human use, and here that covers everything

Did the consultation ask about history and medication?

Which nation, and which ICB if you are in England?

The scheme cap in Ireland was the single most useful thing I learned in a year of reading this board.

Discharge from a specialist service at goal is a normal end point of that pathway. Whether prescribing continues in primary care afterwards is a local decision and is worth asking about at the start rather than at the end.

GP said no and specialist said yes is a very common sequence

stepping every four weeks is a ceiling on speed, not a schedule you must hit